Posted from: Thursday, September 18, 2014 - 02:44 PM - Present

Plegridy Approved for the Treatment of Multiple Sclerosis

August 15, 2014 – Plegridy (peginterferon beta-1a) was approved by the Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS).  Plegridy is manufactured by Biogen Idec.

Plegridy is administered via subcutaneous (SC) injection and to be administered by every two weeks. It is anticipated that Plegridy will replace Biogen’s Avonex which is administered weekly via an intramuscularly.

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Wednesday, September 20, 2017 - 04:02 PM.